Efficacy and Safety of Generic (Velpatasvir containing regimen) among Adult Chronic HCV Patients Non-responders to Treatment by Sofosbuvir Plus Daclatasvir Regimen in Egypt
M. Fares1, E., M. Ragab, W., A. Eldash, H., R. Ismael, N., A. Gomaa, A. (2023). Efficacy and Safety of Generic (Velpatasvir containing regimen) among Adult Chronic HCV Patients Non-responders to Treatment by Sofosbuvir Plus Daclatasvir Regimen in Egypt. EKB Journal Management System, 46(3), 11-24. doi: 10.21608/djs.2023.302744
Eman M. Fares1; Wessam M. Ragab; Heba A. Eldash; Naglaa R. Ismael; Ahmed A. Gomaa. "Efficacy and Safety of Generic (Velpatasvir containing regimen) among Adult Chronic HCV Patients Non-responders to Treatment by Sofosbuvir Plus Daclatasvir Regimen in Egypt". EKB Journal Management System, 46, 3, 2023, 11-24. doi: 10.21608/djs.2023.302744
M. Fares1, E., M. Ragab, W., A. Eldash, H., R. Ismael, N., A. Gomaa, A. (2023). 'Efficacy and Safety of Generic (Velpatasvir containing regimen) among Adult Chronic HCV Patients Non-responders to Treatment by Sofosbuvir Plus Daclatasvir Regimen in Egypt', EKB Journal Management System, 46(3), pp. 11-24. doi: 10.21608/djs.2023.302744
M. Fares1, E., M. Ragab, W., A. Eldash, H., R. Ismael, N., A. Gomaa, A. Efficacy and Safety of Generic (Velpatasvir containing regimen) among Adult Chronic HCV Patients Non-responders to Treatment by Sofosbuvir Plus Daclatasvir Regimen in Egypt. EKB Journal Management System, 2023; 46(3): 11-24. doi: 10.21608/djs.2023.302744

Efficacy and Safety of Generic (Velpatasvir containing regimen) among Adult Chronic HCV Patients Non-responders to Treatment by Sofosbuvir Plus Daclatasvir Regimen in Egypt

Delta Journal of Science
Article 2, Volume 46, Issue 3, June 2023, Page 11-24  XML PDF (679.86 K)
Document Type: Research and Reference
DOI: 10.21608/djs.2023.302744
View on SCiNiTO View on SCiNiTO
Authors
Eman M. Fares11; Wessam M. Ragab2; Heba A. Eldash2; Naglaa R. Ismael2; Ahmed A. Gomaa1
1Endemic Disease and Liver Department, Faculty of Medicine, Fayoum University, Egypt
2Zoology Department, Faculty of Science, Fayoum University, Egypt
Abstract
Hepatitis C is caused by the hepatitis C virus. Various treatments
for hepatitis C were ineffective before the use of direct-acting antivirals
(DAAs). DAA has few (negative) adverse effects and high sustained
virologic response rate (SVR12).
The aim of this study was to investigate the efficacy and safety of
(Velpatasvir-containing regimen) in adult chronic HCV patients
unresponsive to Sofosbuvir plus Daclatasvir in Egypt. Patients were
assessed clinically and laboratory at the baseline before beginning
treatment regimen and monitored clinically and laboratory weekly in the
follow up visits for 12 weeks, we report the adverse events t for the
safety of the drug. At 12 weeks after treatment, RT-PCR was used to
evaluate efficacy. A total of 102 patients. The average age was 55.64 ±
11.13 years old, with (87.3%) male and (12.7%) female. Most patients
were treated with SOF+DAC for 3 months 72 (70.6%) while, 30 patients
(29.4%) were treated with SOF+DAC+RBV for the same duration.
SOF/VEL/VOX therapy had no adverse side effects. The SVR12 rate is
97%. In patients who failed Sofosbuvir plus daclatasvir combination
therapy, this study found that combination therapies containing
velpatasvir are effective and safe for treating HCV in Egypt
Keywords
Hepatitis C; Sofosbuvir/ Velpatasevir / Voxilaprevir; Direct-acting antivirals; Ribvirin; Daclatasvir
Statistics
Article View: 151
PDF Download: 70